Meet the Newest Cohort of Innovative Health Tech Startups

Acellus Health is a healthcare technology company that turns complex clinical records into structured, actionable data. Its ACE Engine reads medical records, extracts required data elements into standard formats such as FHIR, and links every extracted value to its source text. The company offers three solutions: Prior Authorization, which streamlines documentation and approval workflows; Cancer Registry Extraction, which reduces manual chart review for oncology abstraction; and Research Datasets, which convert clinical records into research-ready data. Its approach centers on accuracy, auditability, and clinician review, and the engine is designed to run inside the health system's environment. 

Bewe is a Swiss digital health company helping people reduce their cravings and manage their metabolic health through neurocognitive training. Its approach retrains the brain's automatic reward response to food cues, so patients sustain results without relying on willpower, and is backed by published, peer-reviewed randomized-trial evidence. The company is building an AI personalization layer, grounded in its patented digital behavioral biomarker of human motivation, to profile cravings, personalize interventions, and flag who is most at risk of relapse, including patients who regain weight after stopping GLP-1 medications. 

Cardio4D is an AI-native cardiac digital twin that transforms how structural heart teams plan mitral valve interventions. Using standard pre-procedural CT scans, with no new scan or workflow, its automatically reconstructs a patient-specific 4D heart model and generates accurate, fast and reproducible measurements for procedure planning. Beyond imaging, Cardio4D simulates how a device will behave in each patient's own anatomy, including TMVR deployment to predict LVOT obstruction risk, the step no other tool performs today. Where incumbents stop at static measurements and overlays, Cardio4D models the underlying biomechanics, empowering clinicians to plan with precision and treat with confidence. 

The CibyLink Project, led by healthcare technology company World Life Mapping Inc., addresses the pre-disease stage for working people through two pillars. The CibyLink Platform, used by 110+ hospitals, forecasts key organizational metrics, such as mental-health leave, turnover, and quality and safety indicators, and guides improvement before they deteriorate. The second pillar keeps individuals healthy: identifying disease risk early, prompting timely screening and preventive action, and enabling early detection and treatment when illness occurs. 

askYori is a health technology company founded by doctors and researchers. Its AI health companion, Yori, translates medical research into plain language and delivers personalized guidance tailored to each patient’s conditions and disease stage, from early diagnosis through advanced care. Grounded in verified sources, Yori anticipates what patients need next, connecting them with clinical trials, specialists, and evidence-based lifestyle strategies between visits. askYori’s mission is to help care teams intervene earlier, reduce care gaps, and improve outcomes for patients with complex, chronic, or oncologic conditions. Working with patient communities, clinicians, and health systems, askYori supports more informed care decisions. 

Corpus AI is a Colombian-headquartered, Delaware-incorporated digital-health company that runs six non-generative machine-learning models (AMI, stroke, hypertension, type 2 diabetes, CKD, heart failure) in production for Colombian hospitals and EPS. Built on XGBoost and Random Forest with bootstrap calibration, our platform turns structured EHR data into calibrated probabilities and operational priority scores so clinicians and case managers can rank chronic-disease panels with finite intervention budgets, capturing the highest possible fraction of future events in the top decile of predicted risk. Corpus AI publishes peer-reviewed evidence and operates under strict reproducibility and clinical-veto governance. 

Cortical Dynamics is an Australian perioperative technology company, building medical devices and clinical AI applications for better surgical care. Cortical Dynamics' technologies include BARM™-A next-generation brain and pain monitoring device for use in operating theatres and the ICU.BARM™ individualises anaesthetic depth assessment per patient and incorporates deep learning to read EEG beyond standard monitoring. CORDYAN™, a perioperative patient management platform helping clinicians optimise care across the surgical journey; it addresses fragmented clinical decisions, using AI to transform perioperative patient data into predictive insights, personalised risk assessments and actionable care recommendations 

Elli Cares is an AI-powered care platform helping older adults live independently while giving families and healthcare providers greater visibility into their health and wellbeing between appointments. Combining medication management, daily wellbeing tracking, family observations and behavioural insights, Elli helps care teams identify emerging risks, intervene earlier and deliver more proactive, personalised care. Working with healthcare and aged care providers, Elli aims to reduce avoidable hospitalisations, ease caregiver burden and improve outcomes for ageing populations. Through the Mayo Clinic Platform Accelerate programme, Elli is advancing its predictive AI capabilities to support earlier identification of health and functional decline. 

EO 360º is a clinician-governed, predictive symptom management platform designed to replace fragmented, reactive care with personalized, preventative supportive care across prescription medications, OTC therapies, supplements, nutrition, behavioral care, integrative therapies, and cannabinoids. Using each patient’s clinical history, treatment regimen, labs, symptoms, medications, preferences, and longitudinal outcomes, 360º predicts symptom burden, recommends a net-benefit care plan, applies safety rules, predicts escalation risk, and continuously adapts care. Our beachhead is oncology, where uncontrolled symptoms drive avoidable ER visits, hospitalizations, treatment disruption, and high clinical workload.  360º is designed for both clinical and retail health applications for high symptom burden populations. 

Gauss is a clinical intelligence platform for physicians in ambulatory and primary care. It combines evidence retrieval with longitudinal patient context. Clinicians ask questions in natural language and receive source-cited answers drawn from tens of millions of peer-reviewed articles, clinical trials, medication references and rare-disease databases, with Bayesian probability models ranking candidate conditions for clinician review. Gauss also analyzes the longitudinal record — labs, vitals, medications and encounters — to surface patients at risk of avoidable deterioration earlier, while there is still time to act. Gauss supports clinical judgment; it does not replace it. 

GeneSilico offers gSage, an AI-native precision oncology platform that models each patient's biological state as a molecular-level Digital Twin, matches personalized therapies, and learns from every outcome. From any modality of test, gSage applies AI-labeling to assemble each patient's data into a continuous, longitudinal context, the Casebook; oncologists annotate and decide therapy selection within the platform. Outcomes of the selected therapy, measured through tests including minimal residual disease panels, are incorporated into the Casebook, recalibrating the model and compounding its learnings. That context then serves clinical workflows, including virtual tumor boards, next line of therapy, clinical trial matching, and more. 

gheorg is an AI-powered emotional wellbeing platform for children aged 4–12, used in 78 countries and delivered through schools, health systems and governments. Children talk with child-safe AI characters, co-designed with more than 600 children, that offer evidence-based support drawn from CBT, ACT, positive psychology and play. Every interaction is governed by VERA-MH-P, gheorg's patent-pending AI safety framework for children's mental health. Through Mayo Clinic Platform_Accelerate, gheorg is using de-identified electronic health record data to develop a paediatric mental health risk classifier, helping health systems identify children who may need earlier support before their needs escalate. 

Healthena™ is a next-generation longevity and preventive health platform that transforms fragmented health data into a continuously evolving picture of an individual’s health trajectory. By bringing together laboratory results, vitals, wearables, medications, diagnostics, and clinical history, Healthena applies AI-powered health intelligence and multi-system phenotyping to identify meaningful changes and emerging risks earlier—before they become clinically apparent. Patients gain an intelligent, longitudinal view of their health, while physicians gain powerful decision-support tools designed to advance P4 Medicine: predictive, preventive, personalized, and participatory care. Developed by Healthspan A.I. Corporation, Healthena is designed to move healthcare from episodic intervention toward continuous, proactive healthspan optimization

Hi-D Imaging is a Swiss medical technology company developing cloud-native, AI-driven solutions for cardiovascular imaging and pre-procedural planning. Its flagship 4TAVR platform includes FDA 510(k)-cleared software that automates complex TAVR planning workflows, improving speed, consistency, reproducibility, and operational efficiency while reducing interobserver variability. Building on this foundation, Hi-D Imaging is expanding its technology platform across cardiovascular diseases and interventions. The company serves hospitals, heart centers, medical device manufacturers, and research organizations worldwide, with a mission to bring an intelligent, data-driven layer to clinical decision-making and advance precision cardiovascular care. 

HosTalky is building a Clinical Workflow Intelligence Platform that starts where the burden is heaviest: documentation. Its AI Scribe listens to the patient encounter and turns it into structured notes ready for review. Around it, HosTalky connects the rest of the clinical day — team coordination, reminders, and secure clinician-to-clinician communication — on mobile and desktop alike. Already piloting with healthcare teams in Canada and Brazil, HosTalky is working with Mayo Clinic Platform Accelerate to bring clinical-grade intelligence to every step of care. 

Kihealth is building a new category of precision diagnostics around a powerful idea: people should know what is happening in their bodies before disease changes their lives. Its molecular intelligence platform uses organ-specific cell-free DNA to detect the earliest signals of cellular injury, creating a window into disease biology before traditional diagnostics can see it. That window creates something medicine has never had enough of: time. Time to intervene earlier, protect healthy tissue, measure therapeutic response, and change disease trajectories. Beginning with diabetes and expanding across major diseases, Kihealth envisions a future where medicine doesn’t wait for disease; it sees it coming. 

OncoSeer Diagnostics, Inc. is pioneering a novel clinical decision-support platform to predict, monitor, and diagnose immune-related adverse events (irAEs) in patients receiving immune checkpoint inhibitor (ICI) therapy. While ICI has transformed cancer care, its broader use is limited by unpredictable toxicities that are often difficult to diagnose, may affect any organ system, and can be severe or fatal. Nearly half of treated patients develop some form of irAE and severe irAE’s can lead to treatment discontinuation yet clinicians still lack reliable tools to identify high-risk patients or guide monitoring and diagnosis consistently across care settings. 

POD Health is a precision neuropsychiatry company building an integrated decision-support platform for the diagnosis, pharmacological management, and longitudinal monitoring of neurological and psychiatric conditions across the lifespan; pediatric, adolescent, and adult. Its three integrated components are (1) NeuroPrecision, a pharmacogenomic test built on more than 4,000 curated gene–drug–variant interactions, with CPIC/FDA-aligned rules tiered separately from literature supported associations; (2) OpenMind, a clinical artificial intelligence layer that supports physician decision-making at the point of care; and (3) Piper, a longitudinal patient and family application that captures intervisit symptoms, sleep, mood, adherence, and side effects. The company has pending patents on its pharmacogenomic test and its clinical AI orchestration. 

Hospitals and clinics hold vast CT archives, an untapped asset. Each scan contains more information than the reason it was ordered. Quasar Intelligence is building the infrastructure to unlock it, turning every CT into an early warning system. Quasar calibrates from the scan and corrects for contrast and noise, so scans are comparable across scanners. Its first use case, the Bone Health Index, targets a $57 billion-a-year problem: over 2 million Americans fracture annually, and most do not meet the DXA threshold for osteoporosis. Combined with EHR data, the signals in these scans support care decisions. Foster City, CA. 

Raras Health is a São Paulo-based health AI company working to end the diagnostic odyssey for people with rare diseases. Its flagship product, Raras Care, covers the full patient journey: finding undiagnosed patients, confirming the diagnosis with genomic testing, treatment, long-term follow-up and real-world evidence. The platform combines Rara, a WhatsApp assistant for patients; Pascal, an AI workspace for clinicians; and GEMEO, a patient world model trained on Brazilian longitudinal health data. 

SQK is developing QMEDIC, a computational imaging platform designed to deliver high quality CT images at lower radiation doses. Combining artificial intelligence with physics principles and image fidelity safeguards, QMEDIC refines existing CT images while preserving clinically important structures and quantifying uncertainty. The platform is designed to work across CT systems and integrate into established radiology workflows, supporting clearer visualization and confident image interpretation. Through Mayo Clinic Platform_Accelerate, SQK aims to advance rigorous clinical evaluation and accelerate product development. Its mission is to make precision imaging more accessible and help healthcare providers obtain greater diagnostic value from every CT scan. 

Synagen is an oncology-focused AI company founded in 2024 and headquartered in Germany. Its agentic AI platform extracts information from patient records, including clinical notes, pathology, genomics, medications and labs, and consolidates it into structured patient profiles. These profiles form the foundation for a range of oncology workflows, from cancer registry reporting and administrative documentation to guideline-based clinical decision support, trial matching and tumor board preparation. Developed in close collaboration with 150+ oncologists at leading European cancer centers, the platform is in active use. The founder's foundational research was published in Nature Cancer. 

TinyMoves AI turns ordinary consumer-device video into clinician-reviewable movement and functional measures, without wearables or specialized hardware. Its platform guides patients through standardized motor, gait, fine-motor, and activities-of-daily-living assessments, then returns structured measures mapped to clinical scales used in documentation, care decisions, and trial endpoints. Built on peer-reviewed neuromotor AI research with UPenn and UCSF collaborators, TinyMoves is advancing staged evidence generation across rehabilitation, neurology, and oncology, with active rehabilitation deployment and remote-therapeutic-monitoring workflow validation. Our evidence strategy links video-derived measures to the real-world clinical outcomes clinicians already use. 

Veridata Health builds the governed execution layer for precision medicine, so that every result reaches an accountable decision. Its platform reads clinical and genomic records, applies the rules an institution sets, routes each finding to a named owner, and records what happened, with the data staying inside the institution. Veridata is live with a national diagnostics lab and is extending the same engine to screening, survivorship and diagnostic follow-through in oncology. The company was founded by a diagnostics infrastructure leader from Guardant Health and Quest Diagnostics. 

Welltory is a consumer health app that helps people live happier, healthier lives with data and AI. With 17M installs and over 80% of its paid users in the United States, Welltory turns wearable and smartphone data into personalized, science-based health insights. About 60% of its users live with at least one chronic condition, and Welltory focuses on this audience — translating heart rate variability and activity data into safe, personalized guidance for managing stress, sleep, energy, blood pressure, and recovery between clinical visits. Recognized by Apple, Deloitte Technology Fast 500, and Best of Apps globally, Welltory integrates with 1,000+ devices. 

A.I. VALI (AIV) is a leading AI-driven healthcare company revolutionizing medical imaging with AIDREA, an advanced real-time AI platform for diagnostic accuracy, workflow automation, and clinical and billing reporting. Paired with AIVALInk, our secure cloud-based system, we optimize healthcare efficiency, reduce costs, and accelerate clinical trials, delivering >20X ROI for providers. 

Cardio AI is an AI-powered platform designed to transform cardiovascular care. Our system connects three core components; AI-driven clinical analysis, real-time patient device monitoring, and medical imaging analysis into one unified platform. We offer five validated heart disease risk calculators that predict the likelihood of heart attacks, strokes, heart failure, sudden cardiac death, and irregular heart rhythms. We also provide a dedicated women's cardiovascular health platform that addresses the unique risks women face during pregnancy and postpartum, where heart disease is the leading cause of maternal death. The cardioPro detect 30-90 days MACE risk and provides payer analytics to payers. Our technology helps doctors detect problems earlier, make better treatment decisions. 

DxDepth is redefining clinical decision-making with an AI-powered intelligence platform built for the next era of medicine. Combining real-world outcomes from over 2.8 million patients with peer-reviewed research, FDA drug intelligence, and specialty guidelines, DxDepth delivers evidence-grounded, citation-backed clinical answers in under 10 seconds. Designed for physicians navigating increasingly complex decisions, DxDepth transforms fragmented medical information into actionable intelligence at the point of care. The platform is defining a new standard in AI-driven clinical intelligence. 

FluidAI Medical is dedicated to transforming surgical care through real-time, data-driven insights across the entire patient journey. Their technologies integrate medical devices, software, and artificial intelligence into platforms that address clinical, operational, and economic challenges across the continuum of surgical care. 

GRAIMED is developing a rapid, non-invasive digital biopsy—using AI to predict tumor genomic alterations directly from routine medical imaging. Its radiogenomics software platform uses AI to analyze MRI scans and identify imaging patterns associated with the genomic alterations of a tumor, delivering actionable diagnostic insights without requiring an additional procedure. This will provide clinicians access to critical molecular information faster when tissue biopsy is risky, unavailable, or delayed. Initially focused on brain and prostate cancer, GRAIMED aims to advance timely, informed precision oncology decisions and expand access to precision-level care across both leading academic medical centers and community healthcare settings. 

Healthplus.ai equips surgical teams to predict, detect, and resolve complications early. Healthplus’s first product, PERISCOPE®, is a certified AI medical device that accurately predicts which patients will develop an infection after surgery, days before symptoms appear. PERISCOPE runs inside the hospital's electronic health record and uses data the hospital already has. Healthplus.ai aims to become the risk management platform for all surgeries.